The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19
© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland..
BACKGROUND: Contradictory opinions exist regarding the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with hypertension, which is the most common comorbidity associated with COVID-19. Herein, the effects of ACEIs and ARBs on outcomes of COVID-19 patients were evaluated.
METHODS: In this cross-sectional study, the outcomes of COVID-19 patients were compared between patients who received pretreatment ACEIs or ARBs and those who did not.
RESULTS: The incidence of moderate and severe forms of COVID-19 was significantly higher in patients taking ACEI/ARB drugs (P-value = 0.012). Also, patients taking ACEI/ARB drugs (P-value = 0.034), patients with hypertension (P-value = 0.011), and patients with dyslipidemia (P-value = 0.011) experienced more severe forms of COVID-19. There was an association between increased length of hospital stay and dyslipidemia (P-value = 0.033) and the use of ACEI/ARB drugs (P-value = 0.041), while no correlation was found between other parameters in univariate linear regression analysis as well as multivariate linear regression. There was an association between increased mortality of patients with increasing age (P-value < 0.001), BMI greater than 30 kg/m2 (P-value = 0.02), asthma (P-value = 0.003), and dyslipidemia (P-value = 0.045).
CONCLUSIONS: ACEI/ARB drugs put COVID-19 patients at high risk for moderate to severe forms of COVID-19 and higher length of hospital stay. Although, it is notable that these drugs did not significantly affect specific adverse outcomes of COVID-19, such as the need for admission to the intensive care unit (ICU), length of ICU stay, ventilation, and mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:192 |
|---|---|
| Enthalten in: |
Irish journal of medical science - 192(2023), 3 vom: 20. Juni, Seite 1517-1523 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Najafi, Narges [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin Receptor Antagonists |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 12.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11845-022-03096-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343742896 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343742896 | ||
| 003 | DE-627 | ||
| 005 | 20231226021147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11845-022-03096-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343742896 | ||
| 035 | |a (NLM)35854192 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Najafi, Narges |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 12.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland. | ||
| 520 | |a BACKGROUND: Contradictory opinions exist regarding the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with hypertension, which is the most common comorbidity associated with COVID-19. Herein, the effects of ACEIs and ARBs on outcomes of COVID-19 patients were evaluated | ||
| 520 | |a METHODS: In this cross-sectional study, the outcomes of COVID-19 patients were compared between patients who received pretreatment ACEIs or ARBs and those who did not | ||
| 520 | |a RESULTS: The incidence of moderate and severe forms of COVID-19 was significantly higher in patients taking ACEI/ARB drugs (P-value = 0.012). Also, patients taking ACEI/ARB drugs (P-value = 0.034), patients with hypertension (P-value = 0.011), and patients with dyslipidemia (P-value = 0.011) experienced more severe forms of COVID-19. There was an association between increased length of hospital stay and dyslipidemia (P-value = 0.033) and the use of ACEI/ARB drugs (P-value = 0.041), while no correlation was found between other parameters in univariate linear regression analysis as well as multivariate linear regression. There was an association between increased mortality of patients with increasing age (P-value < 0.001), BMI greater than 30 kg/m2 (P-value = 0.02), asthma (P-value = 0.003), and dyslipidemia (P-value = 0.045) | ||
| 520 | |a CONCLUSIONS: ACEI/ARB drugs put COVID-19 patients at high risk for moderate to severe forms of COVID-19 and higher length of hospital stay. Although, it is notable that these drugs did not significantly affect specific adverse outcomes of COVID-19, such as the need for admission to the intensive care unit (ICU), length of ICU stay, ventilation, and mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Angiotensin receptor blockers (ARBs) | |
| 650 | 4 | |a Angiotensin-converting enzyme inhibitors (ACEIs) | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Outcome | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 700 | 1 | |a Davoudi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Izadyar, Hamideh |e verfasserin |4 aut | |
| 700 | 1 | |a Alishahi, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Mokhtariani, Armaghan |e verfasserin |4 aut | |
| 700 | 1 | |a Soleimanpourian, Bahareh |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarrayi, Mina |e verfasserin |4 aut | |
| 700 | 1 | |a Moosazadeh, Mahmood |e verfasserin |4 aut | |
| 700 | 1 | |a Daftarian, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Ahangarkani, Fatemeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Irish journal of medical science |d 1945 |g 192(2023), 3 vom: 20. Juni, Seite 1517-1523 |w (DE-627)NLM000148970 |x 1863-4362 |7 nnns |
| 773 | 1 | 8 | |g volume:192 |g year:2023 |g number:3 |g day:20 |g month:06 |g pages:1517-1523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11845-022-03096-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 192 |j 2023 |e 3 |b 20 |c 06 |h 1517-1523 | ||